LGD-4033, also known as Ligandrol, is a non-steroidal selective androgen receptor modulator (SARM) developed to selectively stimulate androgen receptors in skeletal muscle and bone. Its high affinity and tissue-selectivity make it a prominent compound in studies focused on increasing lean muscle mass while avoiding the unwanted side effects typically associated with anabolic steroids.

Research has demonstrated that LGD-4033 can enhance protein synthesis, improve physical strength, and support bone density, making it relevant in investigations related to muscle wasting, rehabilitation, and osteoporosis. It does not convert to estrogen or DHT, offering a controlled hormonal profile ideal for studies requiring anabolic stimulation with reduced systemic hormonal disruption. Its oral bioavailability and favorable safety profile have made it a popular model compound in preclinical and clinical research targeting sarcopenia and other degenerative muscle conditions.